Clinical Trials Logo
  1. Home
  2. Brain Metastases, Adult
  3. NCT05999357

JDQ443 for KRAS G12C NSCLC Brain Metastases — STRIDER  

Brain Metastases, Adult Clinical Trial

Official title:
A Phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts With KRAS G12C+ NSCLC and bRain Metastases

Clinical Trial Summary

The goal of this phase II clinical trial is to evaluate the intracranial efficacy of JDQ443, a KRAS G12C inhibitor in patients with KRAS G12C+ NSCLC and brain metastases (cohort A: asymptomatic, untreated brain metastases, cohort B: asymptomatic, treated brain metastases). The main question it aims to answer is to evaluate the intracranial efficacy, according to RANO-BM criteria, in patients with asymptomatic and untreated brain metastases. Participants will receive JDQ443 200 mg BID until unacceptable toxicity or disease progression.

Clinical Trial Description

In the past decade, the treatment and prognosis of patients with metastatic non-small cell lung cancer (NSCLC) has significantly improved, due to new systemic treatments (i.e. intravenous or oral therapy). NSCLC is increasingly subtyped based on the presence of certain mutations in the NSCLC for which targeted therapies have become available. KRAS G12C is the most commonly found mutation, and recently oral therapies (sotorasib in the EU and USA, adagrasib in the USA) have become available. Brain metastasis (BM) incidence in patients with KRAS G12C+ non-small cell lung cancer (NSCLC) is high, but unfortunately, except for one small trial with adagrasib, patients with BM were excluded from most clinical trials with KRAS G12C inhibitors. Furthermore, sotorasib is not very well able to reach the central nervous system (CNS). Adagrasib can penetrate into the CNS, but this comes with relevant treatment related toxicity (mainly gastro-intestinal and liver). JDQ443 is a new oral KRAS G12C inhibitor, that preclinically has the same ability as adagrasib to reach the CNS, but based on small series seems to have less toxicity. As toxicity seems favourable for JDQ443 compared with sotorasib and adagrasib, and as preclinically, CNS penetration seems comparable to adagrasib, data regarding the efficacy of JDQ443 on BM is urgently needed. Therefore the main objective of this trial is to evaluate the intracranial efficacy of JDQ443 in patients with KRAS G12C+ NSCLC and asymptomatic untreated BM. Furthermore, there will be an exploratory cohort for patients with asymptomatic and treated BM. The intervention consists of JDQ443 200 mg BID until unacceptable toxicity or disease progression. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05999357
Study type Interventional
Source Maastricht University Medical Center
Contact
Status Withdrawn
Phase Phase 2
Start date April 15, 2024
Completion date August 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05428852 - Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases N/A
Recruiting NCT05559853 - Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Recruiting NCT05689619 - SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET) N/A
Recruiting NCT04197297 - Brain Imaging Biomarkers in Patients With Brain Metastasis Phase 2
Recruiting NCT04397978 - Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
Terminated NCT04434560 - Neoadjuvant Immunotherapy in Brain Metastases Phase 2
Active, not recruiting NCT05095766 - Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
Recruiting NCT05012254 - Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases Phase 2
Recruiting NCT05789589 - Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases Phase 1/Phase 2
Recruiting NCT06280300 - Multi-disciplinary Care for Brain Metastases N/A
Recruiting NCT06047379 - Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Phase 1/Phase 2
Completed NCT03896555 - Intrafractional Head Movement During Radiosurgery
Terminated NCT03789149 - Focal Intraoperative Radiotherapy of Brain Metastases Phase 2
Recruiting NCT04343157 - UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases Phase 2
Recruiting NCT04711824 - Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases Phase 1/Phase 2
Recruiting NCT05793489 - Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin N/A
Recruiting NCT04461418 - Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases Phase 2
Active, not recruiting NCT03818386 - Radiotherapy of Multiple Brain Metastases Using AGuIX® Phase 2
Active, not recruiting NCT05087095 - Managing Distress in Malignant Brain Cancer N/A
Recruiting NCT04396717 - Safety Study of Pritumumab in Brain Cancer Phase 1